Orally Dissolving Melatonin Formulation with Acidifying Agent

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional oral melatonin treatments face issues with low and variable bioavailability due to the high pH of the saliva and tongue, which reduces the solubility and absorption of melatonin, leading to unpredictable dosing.

Innovation Solution

Formulating melatonin compositions with an acidifying agent, such as citric acid, to lower the pH in the mouth, enhancing solubility and absorption through the oral mucosa, using dosage forms like sublingual or buccal tablets or oral strips that disintegrate quickly and maintain a pH of 4 or less, ensuring rapid absorption.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional oral melatonin dosage forms are used, then the dosage form is simple to manufacture and administer, but the bioavailability is low and variable due to high saliva pH reducing melatonin solubility

Engineering Contradiction:
ImprovebioavailabilityVSAvoiddosage form complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the pH parameter of the oral environment by incorporating acidifying agents (citric acid, malic acid, or ascorbic acid) into the dosage form. These agents lower the saliva pH from its natural higher value to below 4.0, which fundamentally changes the solubility parameters of melatonin, transforming it from poorly soluble to highly soluble in the oral cavity, thereby ensuring reliable and predictable bioavailability.

Inventive Principle:
Principle #35Parameter changes

2Loss of time

If orally dissolving dosage forms are used to improve absorption speed, then the time to absorption is reduced, but the dose delivery becomes unreliable and variable

Engineering Contradiction:
Improveabsorption timeVSAvoiddose predictability
Core Design Contradiction:
Loss of timeVSReliability

Solution Approach 1:

The patent simultaneously addresses both speed and reliability by changing the pH parameter. The acidifying agents ensure rapid dissolution (reducing absorption time) while the disintegrants ensure complete breakdown of the dosage form within 10 minutes. The controlled pH environment below 4.0 maintains consistent melatonin solubility throughout the dissolution process, making the dose delivery both fast and predictable.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses a composite dosage form combining multiple functional materials: melatonin (active ingredient), acidifying agents (pH control), and disintegrants (structure breakdown). This composite approach ensures that all components work synergistically to achieve rapid and reliable dose delivery, with each material contributing a specific function that collectively solves the contradiction between speed and predictability.

Inventive Principle:
Principle #40Composite materials

3Reliability

If acidifying agents are added to enhance melatonin solubility, then the bioavailability and absorption rate increase, but the dosage form formulation becomes more complex

Engineering Contradiction:
Improveabsorption consistencyVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs acidifying agents to change the pH parameter of the oral environment, which directly enhances melatonin solubility and absorption consistency. While this adds a formulation component, the chosen acids (citric, malic, or ascorbic acid) are well-established pharmaceutical excipients that integrate smoothly into existing dosage form manufacturing processes, minimizing the actual increase in complexity.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite formulation where acidifying agents are combined with disintegrants and melatonin. This composite approach allows the different components to work together synergistically, where the acidifying agents provide pH control for solubility, while disintegrants provide structural breakdown, creating a unified dosage form that achieves reliable absorption without excessive complexity.

Inventive Principle:
Principle #40Composite materials

4Productivity

If disintegrants are increased to ensure complete dissolution within 10 minutes, then the absorption speed improves, but the dosage form structure becomes less stable

Engineering Contradiction:
Improvedissolution rateVSAvoiddosage form stability
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent uses disintegrants to change the structural stability parameter of the dosage form, enabling rapid disintegration upon contact with saliva. The disintegrants are selected and formulated to provide sufficient structural breakdown within 10 minutes while maintaining adequate stability during storage and handling, achieving the balance between dissolution rate and compositional stability.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach increases the predictability of melatonin absorption and bioavailability by maintaining a soluble form of melatonin in the mouth, providing a more reliable and rapid onset of action compared to conventional orally dissolving dosage forms.

Implementation Method 1

the composition includes an acidifying agent that lowers the pH inside the mouth, which enhances the oral solubility of melatonin

Methodology Applied
Scientific EffectpH adjustment:

Implementation Method 2

The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva

Methodology Applied
Scientific EffectDisintegration:

Implementation Method 3

melatonin may more readily pass through the oral mucosa and into the bloodstream

Methodology Applied
Scientific EffectAbsorption: Absorption (physical)

Data Source

PatentEP3641759B1Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Publication Date: 2024.04.03 SOCIETE DES PRODUITS NESTLE SA

AI summary

A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.